Vancomyzer™
Vancomyzer estimates vancomycin regimens for adults receiving intermittent intravenous therapy. Clinicians can review predicted exposure, model assumptions and published references.
A dose estimate needs context: patient information, measured concentrations and the limits of the model. Vancomyzer presents these alongside regimen comparisons and a clinical note.
- Show the model and assumptions used
- State where evidence or input data are limited
- Keep dosing decisions with the treating clinician
- Provide results that can be reviewed and documented
Clinical pharmacists, antimicrobial stewardship teams, hospital clinicians reviewing dosing options, and learners exploring vancomycin dosing interpretation. It is not for patients or caregivers.
Vancomyzer is a product of Dōsys Health LLC. Mario Cardenas, PharmD, MBA, is an ICU clinical pharmacist and the company’s founder and CEO. He develops the calculator. For questions or research enquiries, use the contact page; methods and results are documented on the evidence page.
The published population model and developer-run checks are not independent clinical validation of Vancomyzer. Independent evaluation with patient data is pending; the evidence status explains what has been checked and what remains to be evaluated.